Coivas review

The regular figures sit above the introductory cards

Coivas advertises semaglutide from $119 and tirzepatide from $199 per month, while its comparison section lists $149 and $229 after the introductory period. The higher amounts are the stated ongoing figures to investigate for budgeting. Ask how long the introduction lasts, which prescription qualifies, and what is charged at the next renewal. A lower card amount and an after-introduction figure should not be combined into a claim that the same low rate continues indefinitely.

There is also a pricing tension to resolve. The comparison table calls the regular offer one flat price, but the wider disclosure says dosage, titration, treatment duration, or provider recommendations may affect the monthly charge. Those statements do not establish an unconditional all-dose guarantee. Request a written quote for the actual preparation, dose, quantity, and supply, with the conditions for later changes. The service should explain how its flat-price description works alongside the qualification rather than leave a patient to choose the more attractive interpretation.

Several basic costs are described as included

Coivas says consultation, prescription, medication, shipping, and ongoing support are included. That helps distinguish its offer from a care membership with a separate pharmacy bill. Ask what follow-up involves, how messages reach the clinician, and whether a scheduled discussion is available. An included-support claim does not establish immediate response or coverage for every additional appointment. The practical value depends on whether you can obtain the help needed when treatment questions arise between shipments.

The public information does not mention bloodwork. That leaves testing and its cost unresolved rather than proving that testing is never needed or automatically excluded under every arrangement. Ask whether existing results are reviewed, whether a clinician may request testing, and who pays if it is required. A price comparison should follow the actual care plan. Silence about one service should not be converted into a clinical policy or a definite extra charge the company has not stated.

A shared clinical group is not a shared company

The clinical provider is named as Arora Health & Aesthetics, LLC in Seattle. That practice also appears in connection with other brands, which is evidence of shared clinical infrastructure rather than common ownership by itself. Ask which practice and clinician will be responsible for your prescription and how to verify their licensure. The seller, medical practice, and dispensing pharmacy have distinct roles, and a named clinical group does not identify every party handling an individual order.

Coivas claims availability across all 50 states. Confirm the selected product and your actual location before assuming universal access. The offering is compounded, without an established branded, oral, or sublingual alternative. Compounded drugs are not FDA approved and should not be treated as equivalents of approved brands. Obtain the pharmacy identity, ingredients, concentration, quantity, storage, and instructions. A familiar molecule does not establish that another provider's injection volumes or directions can safely be carried over unchanged.

Cancellation needs a deadline and confirmation

The site describes subscriptions that can be canceled anytime. Ask how to cancel, when notice must arrive before another order, and what confirmation is provided. Stopping future billing does not establish a refund for medication already prepared or shipped. The introductory-period question also matters here: someone deciding whether to continue needs to know the next charge before the cancellation cutoff, rather than discovering the ongoing amount after a renewal has already processed.

Coivas may interest someone seeking several basic services in one quoted program, with both introductory and regular figures publicly visible. Its main financial uncertainty is the conflict between flat-price language and dose-dependent qualifications. Relevant pregnancy planning, breastfeeding, postpartum, or PCOS circumstances need direct discussion rather than an assumption of specialty care. Choose on a complete continuing quote, identifiable pharmacy and clinician, accessible follow-up, and retained stopping terms, keeping the $149 and $229 figures qualified until the individual offer is clear.